119-HR-8159 Journalist Public Summary
119 · HR 8159 Gynecologic Pain Management Study Act
H.R. 8159 would have HHS study why patients lack adequate pain control during common gynecologic procedures and recommend fixes; it was introduced on March 30, 2026, and is now in the House Energy and Commerce Committee.
Headline Summary
A House bill would direct the Department of Health and Human Services to study barriers to effective pain management during gynecologic procedures and recommend ways to improve access and standards nationwide.
What It Does
H.R. 8159 (the “Gynecologic Pain Management Study Act”) orders HHS to conduct a comprehensive study of why patients and providers face obstacles to pain control during gynecologic procedures—looking at issues like insurance coverage, provider training, and clinic resources. The study must review existing research, commission new research if gaps remain, consult a wide range of stakeholders (patients, clinicians, professional societies, public health and health‑equity experts, and device makers), and send Congress a report with findings and any proposed administrative or legislative fixes within 24 months of enactment.
Who’s For It
- Lead sponsor: Rep. Yassamin Ansari (D‑AZ), joined by two dozen Democratic co‑sponsors including Reps. Joyce Beatty, Julia Brownley, Yvette Clarke, Raja Krishnamoorthi, Ayanna Pressley, Rashida Tlaib, Paul Tonko, Lori Trahan, Nydia Velázquez, Nikema Williams, and Frederica Wilson.
- Stated rationale from the bill text: gather evidence on insurance, training, and resource barriers so patients can access appropriate pain control and providers have the tools and guidance to offer it.
- Equity framing: by requiring consultation with health‑equity experts and patient advocates, supporters aim to surface disparities affecting marginalized communities.
Who’s Against It
- No formal opposition is recorded at introduction (March 30–31, 2026).
- Potential critiques typical of study bills: questions about creating a new federal review instead of acting directly; concerns about cost, duplication with existing research, or federal overreach into clinical practice; and caution about undue influence from industry stakeholders during consultation.
What’s Next
As of March 31, 2026, the bill has been introduced and referred to the House Committee on Energy and Commerce. Next steps could include a committee hearing and markup; if approved, a House floor vote, followed by Senate consideration. If enacted, HHS would begin the study and deliver its report within 24 months of enactment.
Discussion